| Non-Small Cell Lung Carcinoma
Hyrnuo vs Keytruda
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Hyrnuo vs Keytruda with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKeytruda has a higher rate of injection site reactions vs Hyrnuo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Keytruda but not Hyrnuo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hyrnuo
Keytruda
At A Glance
Oral
Twice daily
HER2 kinase inhibitor
IV infusion
Every 3 weeks or Every 6 weeks
PD-1 inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- melanoma
- Non-Small Cell Lung Carcinoma
- Malignant Pleural Mesothelioma
- Squamous cell carcinoma of the head and neck
- Classic Hodgkin Lymphoma
- Mediastinal (Thymic) Large B-Cell Lymphoma
- Urothelial Carcinoma
- Colorectal Carcinoma
- Stomach Carcinoma
- Esophageal carcinoma
- Cervix carcinoma
- Liver carcinoma
- Biliary Tract Cancer
- Merkel cell carcinoma
- Renal Cell Carcinoma
- Endometrial Carcinoma
- Triple-Negative Breast Carcinoma
- Malignant neoplasm of ovary
- Squamous cell carcinoma of skin
Dosing
Non-Small Cell Lung Carcinoma 20 mg orally twice daily with food until disease progression or unacceptable toxicity.
melanoma 200 mg every 3 weeks or 400 mg every 6 weeks IV; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics
Non-Small Cell Lung Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Malignant Pleural Mesothelioma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Squamous cell carcinoma of the head and neck 200 mg every 3 weeks or 400 mg every 6 weeks IV
Classic Hodgkin Lymphoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics
Mediastinal (Thymic) Large B-Cell Lymphoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics
Urothelial Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Colorectal Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics
Stomach Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Esophageal carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Cervix carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Liver carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Biliary Tract Cancer 200 mg every 3 weeks or 400 mg every 6 weeks IV
Merkel cell carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics
Renal Cell Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV as single agent or in combination with axitinib 5 mg orally twice daily or lenvatinib 20 mg orally once daily
Endometrial Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV in combination with carboplatin and paclitaxel, or with lenvatinib 20 mg orally once daily, or as single agent for MSI-H or dMMR tumors
Triple-Negative Breast Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Malignant neoplasm of ovary 200 mg every 3 weeks or 400 mg every 6 weeks IV
Squamous cell carcinoma of skin 200 mg every 3 weeks or 400 mg every 6 weeks IV
Contraindications
—
Adverse Reactions
Most common (>20%) Diarrhea, rash, paronychia, stomatitis, nausea
Serious Diarrhea, pneumonia, dyspnea, pleural effusion
Most common (>=20%) fatigue, musculoskeletal pain, decreased appetite, rash, diarrhea, nausea, cough, dyspnea, constipation, pruritus, hypothyroidism
Serious pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, dermatologic adverse reactions, myocarditis, neurological toxicities, infusion-related reactions, immune-mediated adverse reactions
Postmarketing exocrine pancreatic insufficiency, sclerosing cholangitis
Pharmacology
Sevabertinib is a reversible kinase inhibitor of HER2 (ERBB2) that also exhibits activity against EGFR; it inhibits HER2 phosphorylation and downstream signaling in cancer cells harboring HER2 alterations and demonstrates antitumor activity in NSCLC models with activating HER2 exon 20 mutations.
Pembrolizumab is a PD-1 blocking antibody that releases PD-1 pathway-mediated inhibition of the immune response by preventing the interaction of PD-1 with its ligands PD-L1 and PD-L2, thereby restoring anti-tumor immune response.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hyrnuo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Keytruda
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Hyrnuo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Keytruda
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Hyrnuo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Keytruda
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Hyrnuo.
No savings programs available for Keytruda.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HyrnuoView full Hyrnuo profile
KeytrudaView full Keytruda profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.